GHRP-2

Growth Hormone SecretagogueResearch Use Only

Also known as: Growth Hormone Releasing Peptide 2, Pralmorelin, KP-102

A growth-hormone-releasing peptide that also raises appetite mildly; often paired with CJC-1295.

Dosing quick reference

research reference

Starting dose

100 mcg once daily

Frequency

Once daily (advanced: 2–3×)

Typical range

100–300 mcg per day

Cycle

8–12 weeks on, then take a break

Titration (step-up)

Wk 1–2: 100 → Wk 3–4: 150 → Wk 5–8: 200 → Wk 9+: 250–300 mcg

Half-life

~30 minutes (short-acting)

Route

Subcutaneous (research)

Common use

Studied as a growth-hormone secretagogue and appetite-related signaling peptide in research

Common vial sizes

5 mg · 10 mg

Storage

Lyophilized powder stored refrigerated or frozen away from light; reconstituted solution refrigerated (2–8 °C) and used within a few weeks

Stacking notes

Commonly paired with a GHRH analog such as CJC-1295 No DAC in research protocols

Reported side effects

Increased appetite reported anecdotallyTransient prolactin or cortisol elevation cited in studiesInjection-site reactionWater retention reported anecdotally

Regulatory note: Not an approved therapeutic; sold for research purposes only

Calculate a dose →GHRP-2 on The Peptide Guide →Deeper research reference: literature dose ranges, storage and handling, and where to source in Canada.

Dose figures are ranges commonly referenced in research literature, not recommendations or medical advice. Research-only labeling does not establish that a substance is safe, approved or appropriate for personal use. Consult a qualified healthcare professional about health decisions.